Subcutaneous application of gammanorm®

Non-interventional study on the subcutaneous application of gammanorm®

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN66955626

Enrollment

100

Registered

2014-09-23

Start date

2014-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary immunodeficiency syndromes/severe secondary hypogammaglobulinaemia Haematological Disorders

Interventions

Treatment with gammanorm in routine clinical use will be documented. This includes data about the patient's disease, age, gender, weight, concomitant medication or illness and information about the ap

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of any gender and age, who receive treatment with gammanorm®

Exclusion criteria

Exclusion criteria: Hypersensitivity to any of the components

Design outcomes

Primary

Measure	Time frame
Information about the treatment with gammanorm® in home therapy and the health-related quality of life will collected by using CRFs and appropriate questionnaires (SF-36 and CHQ-PF50).	—

Secondary

Measure	Time frame
Efficacy of treatment will be measured by evaluating laboratory data, if available.	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026